Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.52 |
| ▸ | MDM4 | O15151 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29355117 | 1.00 | CASP3 (0.52) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL29398212 | 1.00 | CASP3 (0.52) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL30896049 | 1.00 | CASP3 (0.52) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL1486287 | 1.00 | CASP3 (0.52) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL1486214 | 1.00 | CASP3 (0.52) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL118209 | 1.00 | CASP3 (0.52) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL119497 | 1.00 | CASP3 (0.52) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL30896048 | 1.00 | CASP3 (0.52) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL1564185 | 1.00 | CASP3 (0.52) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL29398684 | 1.00 | CASP3 (0.52) | CASP3MDM4TP53KMT2APIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748847-A1 | PEPTIDE COMPLEX HAVING VEGFR -2 AGONIST ACTIVITY | Peptidream Inc (JP) | 2026-05-27 | — | — | EP | disclosed |
| EP-3681875-B1 | CYCLIC PEPTIDE ANTIBIOTICS | HOFFMANN LA ROCHE (CH) | 2026-01-14 | — | — | EP | disclosed |
| US-20250362310-A1 | STRUCTURE-BASED PROBE FOR DETECTION OF TRANSTHYRETIN AMYLOID FIBRILS AND AGGREGATES | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-11-27 | — | — | US | disclosed |
| EP-4631955-A1 | PURIFICATION METHOD AND PRODUCTION METHOD OF CYCLIC PEPTIDE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-10-15 | — | — | EP | disclosed |
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-09 | — | — | US | disclosed |
| US-12404299-B2 | Method for producing peptide compound comprising highly sterically hindered amino acid | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-02 | — | — | US | disclosed |
| US-20250257094-A1 | METHODS FOR PRODUCING CYCLIC COMPOUNDS COMPRISING N-SUBSTITUTED AMINO ACID RESIDUES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-08-14 | — | — | US | disclosed |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-29 | — | — | US | disclosed |
| US-20250230193-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-07-17 | — | — | US | disclosed |
| CN-111148739-B | Cyclic peptide antibiotics | 豪夫迈·罗氏有限公司 | 2025-06-03 | — | — | CN | disclosed |
| WO-2017096311-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | SEATTLE GENETICS, INC. (US) | 2017-06-08 | — | — | WO | disclosed |
| US-8466291-B2 | 1,5-dideoxy-1,5-imino-D-glucitol compounds | ACADEMIA SINICA (TW) | 2013-06-18 | — | — | US | disclosed |
| WO-2012101612-A1 | FMOC SOLID PHASE PEPTIDE SYNTHESIS ON BIODEGRADABLE SUPPORT AND USES THEREOF | The National Institute for Biotechnology in the Negev Ltd. (IL) | 2012-08-02 | — | — | WO | disclosed |
| US-20100113519-A1 | 1,5-Dideoxy-1,5-imino-D-glucitol Compounds | ACADEMIA SINICA (TW) | 2010-05-06 | — | — | US | disclosed |
| US-20100113519-A1 | 1,5-Dideoxy-1,5-imino-D-glucitol Compounds | ACADEMIA SINICA (TW) | 2010-05-06 | — | — | US | disclosed |
| US-20060275213-A1 | Tumor targeting agents and uses thereof | KARYON OY (FI) | 2006-12-07 | — | — | US | disclosed |
| CN-1720258-A | Tumor targeting agents and uses thereof | KARYON OY (FI) | 2006-01-11 | — | — | CN | disclosed |
| EP-1549669-A1 | TUMOR TARGETING AGENTS AND USES THEREOF | Karyon OY (FI) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004031221-A9 | TUMOR TARGETING AGENTS AND USES THEREOF | KARYON OY (FI) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004031221-A1 | TUMOR TARGETING AGENTS AND USES THEREOF | KARYON OY (FI) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | KRAS, HRAS, NRAS | CASP3 2833/4885MDM4 455/4885TP53 8/4885 |
| US-20060275213-A1 | Tumor targeting agents and uses thereof | CCL2, CCL5, SCTR | CASP3 1215/4885MDM4 901/4885TP53 46/4885 |
| US-12404299-B2 | Method for producing peptide compound comprising highly sterically hindered amino acid | DNPEP, VIP, NPEPPS | CASP3 1864/4885MDM4 3528/4885TP53 1753/4885 |
| US-20250230193-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | KRAS, HRAS, NRAS | CASP3 2833/4885MDM4 455/4885TP53 8/4885 |
| US-20250257094-A1 | METHODS FOR PRODUCING CYCLIC COMPOUNDS COMPRISING N-SUBSTITUTED AMINO ACID RESIDUES | NGLY1, NPPA, VIP | CASP3 1858/4885MDM4 266/4885TP53 300/4885 |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | KRAS, NRAS, HRAS | CASP3 3906/4885MDM4 441/4885TP53 34/4885 |
| US-20100113519-A1 | 1,5-Dideoxy-1,5-imino-D-glucitol Compounds | HEXD, GALE, GBA1 | CASP3 3082/4885MDM4 4770/4885TP53 4437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.